Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) FCF Margin: 2022-2025

Historic FCF Margin for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to 0.58%.

  • Axsome Therapeutics' FCF Margin rose 1845.00% to 0.58% in Q3 2025 from the same period last year, while for Sep 2025 it was -18.07%, marking a year-over-year increase of 2118.00%. This contributed to the annual value of -33.36% for FY2024, which is 2047.00% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' FCF Margin is 0.58%, which was up 102.67% from -21.62% recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' FCF Margin peaked at 0.58% during Q3 2025, and registered a low of -135.49% during Q3 2022.
  • Its 3-year average for FCF Margin is -42.16%, with a median of -34.60% in 2024.
  • The largest annual percentage gain for Axsome Therapeutics' FCF Margin in the last 5 years was 8,420bps (2024), contrasted with its biggest fall of 6,519bps (2024).
  • Over the past 4 years, Axsome Therapeutics' FCF Margin (Quarterly) stood at -113.84% in 2022, then soared by 7,138bps to -42.46% in 2023, then soared by 2,037bps to -22.09% in 2024, then spiked by 1,845bps to 0.58% in 2025.
  • Its FCF Margin was 0.58% in Q3 2025, compared to -21.62% in Q2 2025 and -35.99% in Q1 2025.